Tom H M Ottenhoff

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8955456/publications.pdf

Version: 2024-02-01

310 papers	23,324 citations	5574 82 h-index	11308 136 g-index
330 all docs	330 docs citations	330 times ranked	22810 citing authors

#	Article	IF	Citations
1	Lung epithelial cells interact with immune cells and bacteria to shape the microenvironment in tuberculosis. Thorax, 2022, 77, 408-416.	5.6	23
2	Transcriptomic signatures induced by the Ebola virus vaccine rVSVÎ”G-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study. Lancet Microbe, The, 2022, 3, e113-e123.	7.3	6
3	Effects of BCG vaccination on donor unrestricted T cells in two prospective cohort studies. EBioMedicine, 2022, 76, 103839.	6.1	19
4	Antigen presentation by MHC-E: a putative target for vaccination?. Trends in Immunology, 2022, 43, 355-365.	6.8	12
5	Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches. Trends in Pharmacological Sciences, 2022, 43, 293-304.	8.7	8
6	Stratification of COVID-19 patients based on quantitative immune-related gene expression in whole blood. Molecular Immunology, 2022, 145, 17-26.	2.2	4
7	Defining Discriminatory Antibody Fingerprints in Active and Latent Tuberculosis. Frontiers in Immunology, 2022, 13, 856906.	4.8	12
8	Singleâ€Cell Mechanical Characterization of Human Macrophages. Advanced NanoBiomed Research, 2022, 2, .	3.6	4
9	Recombinant BCG-LTAK63 Vaccine Candidate for Tuberculosis Induces an Inflammatory Profile in Human Macrophages. Vaccines, 2022, 10, 831.	4.4	5
10	Host Transcriptional Signatures Predict Etiology in Community-Acquired Pneumonia: Potential Antibiotic Stewardship Tools. Biomarker Insights, 2022, 17, 117727192210991.	2.5	1
11	Interleukin-6 and Mycobacterium tuberculosis dormancy antigens improve diagnosis of tuberculosis. Journal of Infection, 2021, 82, 245-252.	3.3	19
12	Human Transcriptomic Response to the VSV-Vectored Ebola Vaccine. Vaccines, 2021, 9, 67.	4.4	10
13	The role of donorâ€unrestricted Tâ€cells, innate lymphoid cells, and NK cells in antiâ€mycobacterial immunity. Immunological Reviews, 2021, 301, 30-47.	6.0	20
14	B-Cells and Antibodies as Contributors to Effector Immune Responses in Tuberculosis. Frontiers in Immunology, 2021, 12, 640168.	4.8	49
15	Hostâ€directed therapy to combat mycobacterial infections*. Immunological Reviews, 2021, 301, 62-83.	6.0	71
16	Identification of Reduced Host Transcriptomic Signatures for Tuberculosis Disease and Digital PCR-Based Validation and Quantification. Frontiers in Immunology, 2021, 12, 637164.	4.8	25
17	HIV-Infected Patients Developing Tuberculosis Disease Show Early Changes in the Immune Response to Novel Mycobacterium tuberculosis Antigens. Frontiers in Immunology, 2021, 12, 620622.	4.8	7
18	In-vivo expressed Mycobacterium tuberculosis antigens recognised in three mouse strains after infection and BCG vaccination. Npj Vaccines, 2021, 6, 81.	6.0	8

#	Article	IF	Citations
19	Antibody Subclass and Glycosylation Shift Following Effective TB Treatment. Frontiers in Immunology, 2021, 12, 679973.	4.8	22
20	Pyruvate Dehydrogenase Kinase Inhibitor Dichloroacetate Improves Host Control of Salmonella enterica Serovar Typhimurium Infection in Human Macrophages. Frontiers in Immunology, 2021, 12, 739938.	4.8	5
21	Serum Biomarker Profile Including CCL1, CXCL10, VEGF, and Adenosine Deaminase Activity Distinguishes Active From Remotely Acquired Latent Tuberculosis. Frontiers in Immunology, 2021, 12, 725447.	4.8	25
22	Repurposing diphenylbutylpiperidine-class antipsychotic drugs for host-directed therapy of Mycobacterium tuberculosis and Salmonella enterica infections. Scientific Reports, 2021, 11, 19634.	3.3	6
23	Conventional and Unconventional Lymphocytes in Immunity Against Mycobacterium tuberculosis. , 2021, , 133-168.		0
24	Pharmacological Poly (ADP-Ribose) Polymerase Inhibitors Decrease Mycobacterium tuberculosis Survival in Human Macrophages. Frontiers in Immunology, 2021, 12, 712021.	4.8	6
25	The In Vivo Transcriptomic Blueprint of Mycobacterium tuberculosis in the Lung. Frontiers in Immunology, 2021, 12, 763364.	4.8	4
26	Quantitative Rapid Test for Detection and Monitoring of Active Pulmonary Tuberculosis in Nonhuman Primates. Biology, 2021, 10, 1260.	2.8	2
27	Bioorthogonal Correlative Light-Electron Microscopy of Mycobacterium tuberculosis in Macrophages Reveals the Effect of Antituberculosis Drugs on Subcellular Bacterial Distribution. ACS Central Science, 2020, 6, 1997-2007.	11.3	15
28	Tuberculosis causes highly conserved metabolic changes in human patients, mycobacteria-infected mice and zebrafish larvae. Scientific Reports, 2020, 10, 11635.	3.3	15
29	Combining host-derived biomarkers with patient characteristics improves signature performance in predicting tuberculosis treatment outcomes. Communications Biology, 2020, 3, 359.	4.4	16
30	Peptide Binding to HLA-E Molecules in Humans, Nonhuman Primates, and Mice Reveals Unique Binding Peptides but Remarkably Conserved Anchor Residues. Journal of Immunology, 2020, 205, 2861-2872.	0.8	19
31	Trends in diagnostic methods and treatment of latent tuberculosis infection in a tertiary care center from 2000 to 2017. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1329-1337.	2.9	1
32	Expression and production of the SERPING1-encoded endogenous complement regulator C1-inhibitor in multiple cohorts of tuberculosis patients. Molecular Immunology, 2020, 120, 187-195.	2.2	19
33	Functional Inhibition of Host Histone Deacetylases (HDACs) Enhances in vitro and in vivo Anti-mycobacterial Activity in Human Macrophages and in Zebrafish. Frontiers in Immunology, 2020, 11, 36.	4.8	34
34	Cell-Mediated Immune Responses to in vivo-Expressed and Stage-Specific Mycobacterium tuberculosis Antigens in Latent and Active Tuberculosis Across Different Age Groups. Frontiers in Immunology, 2020, 11, 103.	4.8	21
35	Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination. Npj Vaccines, 2020, 5, 32.	6.0	18
36	Analyzing the impact of Mycobacterium tuberculosis infection on primary human macrophages by combined exploratory and targeted metabolomics. Scientific Reports, 2020, 10, 7085.	3.3	27

#	Article	IF	Citations
37	A Trial of M72/AS01_E Vaccine to Prevent Tuberculosis. New England Journal of Medicine, 2020, 382, 1576-1577.	27.0	6
38	Systemic and pulmonary C1q as biomarker of progressive disease in experimental non-human primate tuberculosis. Scientific Reports, 2020, 10, 6290.	3.3	11
39	Machine Learning Algorithms Evaluate Immune Response to Novel Mycobacterium tuberculosis Antigens for Diagnosis of Tuberculosis. Frontiers in Cellular and Infection Microbiology, 2020, 10, 594030.	3.9	9
40	Host Blood RNA Transcript and Protein Signatures for Sputum-Independent Diagnostics of Tuberculosis in Adults. Frontiers in Immunology, 2020, 11, 626049.	4.8	13
41	HIV Skews a Balanced Mtb-Specific Th17 Response in Latent Tuberculosis Subjects to a Pro-inflammatory Profile Independent of Viral Load. Cell Reports, 2020, 33, 108451.	6.4	5
42	An Internet-Based Psychological Intervention With a Serious Game to Improve Vitality, Psychological and Physical Condition, and Immune Function in Healthy Male Adults: Randomized Controlled Trial. Journal of Medical Internet Research, 2020, 22, e14861.	4.3	6
43	Effectiveness of Stress-Reducing Interventions on the Response to Challenges to the Immune System: A Meta-Analytic Review. Psychotherapy and Psychosomatics, 2019, 88, 274-286.	8.8	37
44	Radiological Signs of Latent Tuberculosis on Chest Radiography: A Systematic Review and Meta-Analysis. Open Forum Infectious Diseases, 2019, 6, .	0.9	19
45	Two-Hit in vitro T-Cell Stimulation Detects Mycobacterium tuberculosis Infection in QuantiFERON Negative Tuberculosis Patients and Healthy Contacts From Ghana. Frontiers in Immunology, 2019, 10, 1518.	4.8	10
46	Mobilizing unconventional T cells. Science, 2019, 366, 302-303.	12.6	20
47	Guidance for Studies Evaluating the Accuracy of Tuberculosis Triage Tests. Journal of Infectious Diseases, 2019, 220, S116-S125.	4.0	33
48	Identification of a systemic interferon-Î³ inducible antimicrobial gene signature in leprosy patients undergoing reversal reaction. PLoS Neglected Tropical Diseases, 2019, 13, e0007764.	3.0	21
49	Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques. Nature Medicine, 2019, 25, 255-262.	30.7	227
50	Optimisation, harmonisation and standardisation of the direct mycobacterial growth inhibition assay using cryopreserved human peripheral blood mononuclear cells. Journal of Immunological Methods, 2019, 469, 1-10.	1.4	28
51	Whole-blood transcriptomic signatures induced during immunization by chloroquine prophylaxis and Plasmodium falciparum sporozoites. Scientific Reports, 2019, 9, 8386.	3.3	24
52	Oxidized low-density lipoprotein (oxLDL) supports Mycobacterium tuberculosis survival in macrophages by inducing lysosomal dysfunction. PLoS Pathogens, 2019, 15, e1007724.	4.7	32
53	Immunometabolic Signatures Predict Risk of Progression to Active Tuberculosis and Disease Outcome. Frontiers in Immunology, 2019, 10, 527.	4.8	40
54	Harnessing donor unrestricted T-cells for new vaccines against tuberculosis. Vaccine, 2019, 37, 3022-3030.	3.8	59

#	Article	IF	Citations
55	Evidence for Highly Variable, Region-Specific Patterns of T-Cell Epitope Mutations Accumulating in Mycobacterium tuberculosis Strains. Frontiers in Immunology, 2019, 10, 195.	4.8	6
56	Abnormalities suggestive of latent tuberculosis infection on chest radiography; how specific are they?. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2019, 15, 100089.	1.3	6
57	Mycobacterium tuberculosis clinical isolates of the Beijing and East-African Indian lineage induce fundamentally different host responses in mice compared to H37Rv. Scientific Reports, 2019, 9, 19922.	3.3	14
58	Whole blood RNA signatures in leprosy patients identify reversal reactions before clinical onset: a prospective, multicenter study. Scientific Reports, 2019, 9, 17931.	3.3	21
59	Disparate Tuberculosis Disease Development in Macaque Species Is Associated With Innate Immunity. Frontiers in Immunology, 2019, 10, 2479.	4.8	27
60	Gene expression profiles classifying clinical stages of tuberculosis and monitoring treatment responses in Ethiopian HIV-negative and HIV-positive cohorts. PLoS ONE, 2019, 14, e0226137.	2.5	10
61	Plasma metabolomics in tuberculosis patients with and without concurrent type 2 diabetes at diagnosis and during antibiotic treatment. Scientific Reports, 2019, 9, 18669.	3.3	41
62	BCG revaccination boosts adaptive polyfunctional Th1/Th17 and innate effectors in IGRA+ and IGRAâ€“ Indian adults. JCI Insight, 2019, 4, .	5.0	48
63	Update on tuberculosis biomarkers: From correlates of risk, to correlates of active disease and of cure from disease. Respirology, 2018, 23, 455-466.	2.3	150
64	Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. Lancet Infectious Diseases, The, 2018, 18, 738-748.	9.1	62
65	Four-Gene Pan-African Blood Signature Predicts Progression to Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1198-1208.	5.6	217
66	Tuberculosis vaccines: Opportunities and challenges. Respirology, 2018, 23, 359-368.	2.3	82
67	Africa-wide evaluation of host biomarkers in QuantiFERON supernatants for the diagnosis of pulmonary tuberculosis. Scientific Reports, 2018, 8, 2675.	3.3	44
68	Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials. Nature Communications, 2018, 9, 358.	12.8	47
69	The SysteMHC Atlas project. Nucleic Acids Research, 2018, 46, D1237-D1247.	14.5	119
70	Detailed characterization of human Mycobacterium tuberculosis specific HLAâ€Ł restricted CD8⁺ TÂcells. European Journal of Immunology, 2018, 48, 293-305.	2.9	39
71	Atypical Human Effector/Memory CD4+ T Cells With a Naive-Like Phenotype. Frontiers in Immunology, 2018, 9, 2832.	4.8	40
72	Metabolite changes in blood predict the onset of tuberculosis. Nature Communications, 2018, 9, 5208.	12.8	129

#	Article	IF	Citations
73	Complement Component C1q as Serum Biomarker to Detect Active Tuberculosis. Frontiers in Immunology, 2018, 9, 2427.	4.8	43
74	Mycobacterial growth inhibition is associated with trained innate immunity. Journal of Clinical Investigation, 2018, 128, 1837-1851.	8.2	144
75	A Systematic Review on Novel Mycobacterium tuberculosis Antigens and Their Discriminatory Potential for the Diagnosis of Latent and Active Tuberculosis. Frontiers in Immunology, 2018, 9, 2476.	4.8	70
76	Correlates of vaccine adjuvanticity, vaccine activity, protective immunity and disease in human infectious disease and cancer. Seminars in Immunology, 2018, 39, 1-3.	5.6	0
77	Cross-laboratory evaluation of multiplex bead assays including independent common reference standards for immunological monitoring of observational and interventional human studies. PLoS ONE, 2018, 13, e0201205.	2.5	15
78	A novel view on the pathogenesis of complications after intravesical BCG for bladder cancer. International Journal of Infectious Diseases, 2018, 72, 63-68.	3.3	12
79	Patients with Concurrent Tuberculosis and Diabetes Have a Pro-Atherogenic Plasma Lipid Profile. EBioMedicine, 2018, 32, 192-200.	6.1	36
80	Borderline QuantiFERON results and the distinction between specific responses and test variability. Tuberculosis, 2018, 111, 102-108.	1.9	14
81	Vaccines for Leprosy and Tuberculosis: Opportunities for Shared Research, Development, and Application. Frontiers in Immunology, 2018, 9, 308.	4.8	23
82	A Serum Circulating miRNA Signature for Short-Term Risk of Progression to Active Tuberculosis Among Household Contacts. Frontiers in Immunology, 2018, 9, 661.	4.8	42
83	Impaired Immune Response to Primary but Not to Booster Vaccination Against Hepatitis B in Older Adults. Frontiers in Immunology, 2018, 9, 1035.	4.8	27
84	Human CD4 T-Cells With a Naive Phenotype Produce Multiple Cytokines During Mycobacterium Tuberculosis Infection and Correlate With Active Disease. Frontiers in Immunology, 2018, 9, 1119.	4.8	24
85	Genome wide approaches discover novel Mycobacterium tuberculosis antigens as correlates of infection, disease, immunity and targets for vaccination. Seminars in Immunology, 2018, 39, 88-101.	5.6	52
86	Host Gene Expression Kinetics During Treatment of Tuberculosis in HIV-Coinfected Individuals Is Independent of Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2018, 218, 1833-1846.	4.0	15
87	Potential of DosR and Rpf antigens from Mycobacterium tuberculosis to discriminate between latent and active tuberculosis in a tuberculosis endemic population of Medellin Colombia. BMC Infectious Diseases, 2018, 18, 26.	2.9	34
88	Retinal Pigment Epithelial Cells Control Early Mycobacterium tuberculosis Infection via Interferon Signaling. , 2018, 59, 1384.		20
89	Antibody glycosylation in inflammation, disease and vaccination. Seminars in Immunology, 2018, 39, 102-110.	5.6	131
90	NF-Î²B/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification. JCI Insight, 2018, 3, .	5.0	63

#	Article	IF	Citations
91	Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials. Vaccine, 2017, 35, 1652-1661.	3.8	47
92	Variable BCG efficacy in rhesus populations: Pulmonary BCG provides protection where standard intra-dermal vaccination fails. Tuberculosis, 2017, 104, 46-57.	1.9	80
93	A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa. Science Translational Medicine, 2017, 9, .	12.4	48
94	Differences in IgG responses against infection phase related Mycobacterium tuberculosis (Mtb) specific antigens in individuals exposed or not to Mtb correlate with control of TB infection and progression. Tuberculosis, 2017, 106, 25-32.	1.9	24
95	South Asian men have lower expression of IFN signalling genes in white adipose tissue and skeletal muscle compared with white men. Diabetologia, 2017, 60, 2525-2528.	6.3	4
96	Circulating Mycobacterium tuberculosis DosR latency antigen-specific, polyfunctional, regulatory IL10+ Th17 CD4 T-cells differentiate latent from active tuberculosis. Scientific Reports, 2017, 7, 11948.	3.3	37
97	Immunological characterization of latent tuberculosis infection in a low endemic country. Tuberculosis, 2017, 106, 62-72.	1.9	12
98	Novel transcriptional signatures for sputum-independent diagnostics of tuberculosis in children. Scientific Reports, 2017, 7, 5839.	3.3	30
99	Proof of concept that most borderline Quantiferon results are true antigen-specific responses. European Respiratory Journal, 2017, 50, 1701630.	6.7	11
100	The effects of a psychological intervention directed at optimizing immune function: study protocol for a randomized controlled trial. Trials, 2017, 18, 243.	1.6	6
101	Interactions between Type 1 Interferons and the Th17 Response in Tuberculosis: Lessons Learned from Autoimmune Diseases. Frontiers in Immunology, 2017, 8, 294.	4.8	56
102	TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development. Frontiers in Immunology, 2017, 8, 1203.	4.8	44
103	Molecular Signatures of Immunity and Immunogenicity in Infection and Vaccination. Frontiers in Immunology, 2017, 8, 1563.	4.8	18
104	Humoral Responses to Rv1733c, Rv0081, Rv1735c, and Rv1737c DosR Regulon-Encoded Proteins of Mycobacterium tuberculosis in Individuals with Latent Tuberculosis Infection. Journal of Immunology Research, 2017, 2017, 1-8.	2.2	23
105	MHC Ib molecule Qa-1 presents Mycobacterium tuberculosis peptide antigens to CD8+ T cells and contributes to protection against infection. PLoS Pathogens, 2017, 13, e1006384.	4.7	47
106	Tuberculosis Biomarkers: From Diagnosis to Protection. Gastroenterology Insights, 2016, 8, 6568.	1.2	129
107	Characteristics of HLA-E Restricted T-Cell Responses and Their Role in Infectious Diseases. Journal of Immunology Research, 2016, 2016, 1-11.	2.2	69
108	Host Immune Responses Differ between M. africanum- and M. tuberculosis-Infected Patients following Standard Anti-tuberculosis Treatment. PLoS Neglected Tropical Diseases, 2016, 10, e0004701.	3.0	43

#	Article	IF	Citations
109	Discriminative expression of whole blood genes in HIV patients with latent and active TB in Ethiopia. Tuberculosis, 2016, 100, 25-31.	1.9	9
110	Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. European Respiratory Journal, 2016, 48, 1751-1763.	6.7	165
111	New Genome-Wide Algorithm Identifies Novel In-Vivo Expressed Mycobacterium Tuberculosis Antigens Inducing Human T-Cell Responses with Classical and Unconventional Cytokine Profiles. Scientific Reports, 2016, 6, 37793.	3.3	69
112	Diagnostic performance of a seven-marker serum protein biosignature for the diagnosis of active TB disease in African primary healthcare clinic attendees with signs and symptoms suggestive of TB. Thorax, 2016, 71, 785-794.	5.6	134
113	Transcriptomic evidence for modulation of host inflammatory responses during febrile Plasmodium falciparum malaria. Scientific Reports, 2016, 6, 31291.	3.3	85
114	Multifunctional T Cell Response to DosR and Rpf Antigens Is Associated with Protection in Long-Term Mycobacterium tuberculosis-Infected Individuals in Colombia. Vaccine Journal, 2016, 23, 813-824.	3.1	31
115	Rewiring cellular metabolism via the AKT/mTOR pathway contributes to host defence against Mycobacterium tuberculosis in human and murine cells. European Journal of Immunology, 2016, 46, 2574-2586.	2.9	118
116	Approaching a diagnostic point-of-care test for pediatric tuberculosis through evaluation of immune biomarkers across the clinical disease spectrum. Scientific Reports, 2016, 6, 18520.	3.3	25
117	BLR1 and FCGR1A transcripts in peripheral blood associate with the extent of intrathoracic tuberculosis in children and predict treatment outcome. Scientific Reports, 2016, 6, 38841.	3.3	8
118	Mycobacterium tuberculosisâ€specific CD4⁺ Tâ€cell response is increased, and Treg cells decreased, in anthelminticâ€treated patients with latent TB. European Journal of Immunology, 2016, 46, 752-761.	2.9	41
119	Dynamics of the T cell response to Mycobacterium tuberculosis DosR and Rpf antigens in a Colombian population of household contacts of recently diagnosed pulmonary tuberculosis patients. Tuberculosis, 2016, 97, 97-107.	1.9	7
120	Detection of IgG1 antibodies against Mycobacterium tuberculosis DosR and Rpf antigens in tuberculosis patients before and after chemotherapy. Tuberculosis, 2016, 96, 65-70.	1.9	17
121	A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet, The, 2016, 387, 2312-2322.	13.7	678
122	KLRG1 and PD-1 expression are increased on T-cells following tuberculosis-treatment and identify cells with different proliferative capacities in BCG-vaccinated adults. Tuberculosis, 2016, 97, 163-171.	1.9	24
123	The effect of HIV coinfection, HAART and TB treatment on cytokine/chemokine responses to Mycobacterium tuberculosis (Mtb) antigens in active TB patients and latently Mtb infected individuals. Tuberculosis, 2016, 96, 131-140.	1.9	19
124	Use of lateral flow assays to determine IP-10 and CCL4 levels in pleural effusions and whole blood for TB diagnosis. Tuberculosis, 2016, 96, 31-36.	1.9	33
125	Multi-center evaluation of a user-friendly lateral flow assay to determine IP-10 and CCL4 levels in blood of TB and non-TB cases in Africa. Clinical Biochemistry, 2016, 49, 22-31.	1.9	49
126	Cell-type deconvolution with immune pathways identifies gene networks of host defense and immunopathology in leprosy. JCI Insight, 2016, 1, e88843.	5.0	29

#	Article	IF	Citations
127	Patients with Tuberculosis Have a Dysfunctional Circulating B-Cell Compartment, Which Normalizes following Successful Treatment. PLoS Pathogens, 2016, 12, e1005687.	4.7	138
128	Regulatory T-Cells at the Interface between Human Host and Pathogens in Infectious Diseases and Vaccination. Frontiers in Immunology, 2015, 6, 217.	4.8	129
129	Pro- and Anti-Inflammatory Cytokines against Rv2031 Are Elevated during Latent Tuberculosis: A Study in Cohorts of Tuberculosis Patients, Household Contacts and Community Controls in an Endemic Setting. PLoS ONE, 2015, 10, e0124134.	2.5	41
130	Intracellular Cytokine Staining and Flow Cytometry: Considerations for Application in Clinical Trials of Novel Tuberculosis Vaccines. PLoS ONE, 2015, 10, e0138042.	2.5	71
131	Acquired immunodeficiencies and tuberculosis: focus on <scp>HIV</scp>/<scp>AIDS</scp> and diabetes mellitus. Immunological Reviews, 2015, 264, 121-137.	6.0	87
132	Ebola vaccine R&D: Filling the knowledge gaps. Science Translational Medicine, 2015, 7, 317ps24.	12.4	41
133	The C-Type Lectin Receptor CLECSF8/CLEC4D Is a Key Component of Anti-Mycobacterial Immunity. Cell Host and Microbe, 2015, 17, 252-259.	11.0	100
134	Biomarkers Can Identify Pulmonary Tuberculosis in HIV-infected Drug Users Months Prior to Clinical Diagnosis. EBioMedicine, 2015, 2, 172-179.	6.1	33
135	Synthetic Long Peptide Derived from Mycobacterium tuberculosis Latency Antigen Rv1733c Protects against Tuberculosis. Vaccine Journal, 2015, 22, 1060-1069.	3.1	32
136	Big Data in Vaccinology: Introduction and section summaries. Vaccine, 2015, 33, 5237-5240.	3.8	2
137	Short-term high-fat diet increases macrophage markers in skeletal muscle accompanied by impaired insulin signalling in healthy male subjects. Clinical Science, 2015, 128, 143-151.	4.3	34
138	Human CD8+ T-cells Recognizing Peptides from Mycobacterium tuberculosis (Mtb) Presented by HLA-E Have an Unorthodox Th2-like, Multifunctional, Mtb Inhibitory Phenotype and Represent a Novel Human T-cell Subset. PLoS Pathogens, 2015, 11, e1004671.	4.7	97
139	Dysregulation of Apoptosis Is a Risk Factor for Tuberculosis Disease Progression. Journal of Infectious Diseases, 2015, 212, 1469-1479.	4.0	22
140	Human CD8 T lymphocytes recognize Mycobacterium tuberculosis antigens presented by HLAâ€E during active tuberculosis and express type 2 cytokines. European Journal of Immunology, 2015, 45, 1069-1081.	2.9	59
141	Mycobacterium bovis BCG Vaccination Induces Divergent Proinflammatory or Regulatory T Cell Responses in Adults. Vaccine Journal, 2015, 22, 778-788.	3.1	55
142	Focused human gene expression profiling using dual-color reverse transcriptase multiplex ligation-dependent probe amplification. Vaccine, 2015, 33, 5282-5288.	3.8	21
143	Clinical Immunology and Multiplex Biomarkers of Human Tuberculosis. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a018515-a018515.	6.2	32
144	CD8+ Regulatory T Cells, and Not CD4+ T Cells, Dominate Suppressive Phenotype and Function after In Vitro Live Mycobacterium bovis-BCG Activation of Human Cells. PLoS ONE, 2014, 9, e94192.	2.5	34

#	Article	IF	Citations
145	Clonal Analysis of the T-Cell Response to In Vivo Expressed Mycobacterium tuberculosis Protein Rv2034, Using a CD154 Expression Based T-Cell Cloning Method. PLoS ONE, 2014, 9, e99203.	2.5	14
146	A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. Vaccine, 2014, 32, 7098-7107.	3.8	199
147	Diagnosis of Childhood Tuberculosis and Host RNA Expression in Africa. New England Journal of Medicine, 2014, 370, 1712-1723.	27.0	324
148	Field-Evaluation of a New Lateral Flow Assay for Detection of Cellular and Humoral Immunity against Mycobacterium leprae. PLoS Neglected Tropical Diseases, 2014, 8, e2845.	3.0	59
149	T-Cell Regulation in Lepromatous Leprosy. PLoS Neglected Tropical Diseases, 2014, 8, e2773.	3.0	67
150	Immunogenicity of 60 novel latency-related antigens of Mycobacterium tuberculosis. Frontiers in Microbiology, 2014, 5, 517.	3.5	86
151	Use of Resuscitation-Promoting Factor Proteins Improves the Sensitivity of Culture-based Tuberculosis Testing in Special Samples. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 612-614.	5.6	22
152	Significance of Antigen and Epitope Specificity in Tuberculosis. Frontiers in Immunology, 2014, 5, 524.	4.8	11
153	Innovative Strategies to Identify M. tuberculosis Antigens and Epitopes Using Genome-Wide Analyses. Frontiers in Immunology, 2014, 5, 256.	4.8	45
154	Longitudinal Immune Responses and Gene Expression Profiles in Type 1 Leprosy Reactions. Journal of Clinical Immunology, 2014, 34, 245-255.	3.8	63
155	Differential gene expression of activating FcÎ³ receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity. Clinical Microbiology and Infection, 2014, 20, O230-O238.	6.0	65
156	TRANSVAC workshop on standardisation and harmonisation of analytical platforms for HIV, TB and malaria vaccines: â€˜How can big data help?â€™. Vaccine, 2014, 32, 4365-4368.	3.8	4
157	Combination of gene expression patterns in whole blood discriminate between tuberculosis infection states. BMC Infectious Diseases, 2014, 14, 257.	2.9	30
158	The in vivo expressed Mycobacterium tuberculosis (IVE-TB) antigen Rv2034 induces CD4+ T-cells that protect against pulmonary infection in HLA-DR transgenic mice and guinea pigs. Vaccine, 2014, 32, 3580-3588.	3.8	25
159	The DNA Damage-Regulated Autophagy Modulator DRAM1 Links Mycobacterial Recognition via TLR-MYD88 to Autophagic Defense. Cell Host and Microbe, 2014, 15, 753-767.	11.0	147
160	The influence of influenza virus infections on the development of tuberculosis. Tuberculosis, 2013, 93, 338-342.	1.9	25
161	Interferon-Î³ responses to Mycobacterium tuberculosis Rpf proteins in contact investigation. Tuberculosis, 2013, 93, 612-617.	1.9	13
162	An Unbiased Genome-Wide Mycobacterium tuberculosis Gene Expression Approach To Discover Antigens Targeted by Human T Cells Expressed during Pulmonary Infection. Journal of Immunology, 2013, 190, 1659-1671.	0.8	83

#	Article	IF	Citations
163	<scp>CD</scp>39 is involved in mediating suppression by <scp>M</scp>ycobacterium bovis<scp>BCG</scp>â€activated human <scp>CD</scp>8⁺<scp>CD</scp>39⁺ regulatory <scp>T</scp>Âcells. European Journal of Immunology, 2013, 43, 1925-1932.	2.9	44
164	Low Induction of Proinflammatory Cytokines Parallels Evolutionary Success of Modern Strains within the Mycobacterium tuberculosis Beijing Genotype. Infection and Immunity, 2013, 81, 3750-3756.	2.2	71
165	Analysis of Host Responses to Mycobacterium tuberculosis Antigens in a Multi-Site Study of Subjects with Different TB and HIV Infection States in Sub-Saharan Africa. PLoS ONE, 2013, 8, e74080.	2.5	48
166	Recombinant ESAT-6-CFP10 Fusion Protein Induction of Th1/Th2 Cytokines and FoxP3 Expressing Treg Cells in Pulmonary TB. PLoS ONE, 2013, 8, e68121.	2.5	22
167	A Helicopter Perspective on TB Biomarkers: Pathway and Process Based Analysis of Gene Expression Data Provides New Insight into TB Pathogenesis. PLoS ONE, 2013, 8, e73230.	2.5	86
168	Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go?. PLoS Pathogens, 2012, 8, e1002607.	4.7	381
169	Peptides Derived fromMycobacterium lepraeML1601c Discriminate between Leprosy Patients and Healthy Endemic Controls. Journal of Tropical Medicine, 2012, 2012, 1-11.	1.7	16
170	A multistage-polyepitope vaccine protects against Mycobacterium tuberculosis infection in HLA-DR3 transgenic mice. Vaccine, 2012, 30, 7513-7521.	3.8	27
171	New pathways of protective and pathological host defense to mycobacteria. Trends in Microbiology, 2012, 20, 419-428.	7.7	132
172	T Cell Assays and MIATA: The Essential Minimum for Maximum Impact. Immunity, 2012, 37, 1-2.	14.3	131
173	Analysis of Immune Responses against a Wide Range of Mycobacterium tuberculosis Antigens in Patients with Active Pulmonary Tuberculosis. Vaccine Journal, 2012, 19, 1907-1915.	3.1	61
174	Potential of Mycobacterium tuberculosis resuscitation-promoting factors as antigens in novel tuberculosis sub-unit vaccines. Microbes and Infection, 2012, 14, 86-95.	1.9	52
175	Common variants at 11p13 are associated with susceptibility to tuberculosis. Nature Genetics, 2012, 44, 257-259.	21.4	195
176	Genome-Wide Expression Profiling Identifies Type 1 Interferon Response Pathways in Active Tuberculosis. PLoS ONE, 2012, 7, e45839.	2.5	213
177	Mycobacterium leprae virulence-associated peptides are indicators of exposure to M. leprae in Brazil, Ethiopia and Nepal. Memorias Do Instituto Oswaldo Cruz, 2012, 107, 112-123.	1.6	17
178	Ten challenges for TB biomarkers. Tuberculosis, 2012, 92, S17-S20.	1.9	50
179	Polymorphisms in SP110 are not associated with pulmonary tuberculosis in Indonesians. Infection, Genetics and Evolution, 2012, 12, 1319-1323.	2.3	18
180	T cell responses to DosR and Rpf proteins in actively and latently infected individuals from Colombia. Tuberculosis, 2012, 92, 148-159.	1.9	50

#	Article	IF	Citations
181	A genome wide association study of pulmonary tuberculosis susceptibility in Indonesians. BMC Medical Genetics, 2012, 13, 5.	2.1	90
182	Potential of Host Markers Produced by Infection Phase-Dependent Antigen-Stimulated Cells for the Diagnosis of Tuberculosis in a Highly Endemic Area. PLoS ONE, 2012, 7, e38501.	2.5	50
183	Genome-Based In Silico Identification of New Mycobacterium tuberculosis Antigens Activating Polyfunctional CD8+ T Cells in Human Tuberculosis. Journal of Immunology, 2011, 186, 1068-1080.	0.8	50
184	Simultaneous Immunization against Tuberculosis. PLoS ONE, 2011, 6, e27477.	2.5	30
185	Ag85Bâ€“ESAT-6 adjuvanted with IC31Â® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine, 2011, 29, 2100-2109.	3.8	117
186	Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines. Vaccine, 2011, 29, 4761-4770.	3.8	65
187	Improved long-term protection against Mycobacterium tuberculosis Beijing/W in mice after intra-dermal inoculation of recombinant BCG expressing latency associated antigens. Vaccine, 2011, 29, 8740-8744.	3.8	32
188	Lateral flow assay for simultaneous detection of cellular- and humoral immune responses. Clinical Biochemistry, 2011, 44, 1241-1246.	1.9	84
189	A High-Throughput Screen for Tuberculosis Progression. PLoS ONE, 2011, 6, e16779.	2.5	101
190	Doubleâ€•and monofunctional CD4⁺ and CD8⁺ Tâ€cell responses to Mycobacterium tuberculosis DosR antigens and peptides in longâ€term latently infected individuals. European Journal of Immunology, 2011, 41, 2925-2936.	2.9	101
191	Evaluation of the high-pressure extrusion technique as a method for sizing plasmid DNA-containing cationic liposomes. Journal of Liposome Research, 2011, 21, 286-295.	3.3	4
192	Identification of Human T-Cell Responses to Mycobacterium tuberculosis Resuscitation-Promoting Factors in Long-Term Latently Infected Individuals. Vaccine Journal, 2011, 18, 676-683.	3.1	67
193	ML1419c Peptide Immunization InducesMycobacterium leprae-Specific HLA-A*0201â€“Restricted CTL In Vivo with Potential To Kill Live Mycobacteria. Journal of Immunology, 2011, 187, 1393-1402.	0.8	12
194	CXCR6 Is a Marker for Protective Antigen-Specific Cells in the Lungs after Intranasal Immunization against Mycobacterium tuberculosis. Infection and Immunity, 2011, 79, 3328-3337.	2.2	55
195	Identification of Probable Early-Onset Biomarkers for Tuberculosis Disease Progression. PLoS ONE, 2011, 6, e25230.	2.5	39
196	Higher Frequency of T-Cell Response to M. tuberculosis Latency Antigen Rv2628 at the Site of Active Tuberculosis Disease than in Peripheral Blood. PLoS ONE, 2011, 6, e27539.	2.5	54
197	Increased IgG1, IFN-Î³, TNF-Î± and IL-6 responses to Mycobacterium tuberculosis antigens in patients with Tuberculosis are lower after chemotherapy. International Immunology, 2010, 22, 775-782.	4.0	68
198	Antiâ€inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitorâ€treated gastrointestinal stromal tumors. International Journal of Cancer, 2010, 127, 899-909.	5.1	92

#	Article	IF	Citations
199	Multifunctional CD4⁺ T cells correlate with active Mycobacterium tuberculosis infection. European Journal of Immunology, 2010, 40, 2211-2220.	2.9	270
200	The other Janus face of Qa-1 and HLA-E: diverse peptide repertoires in times of stress. Microbes and Infection, 2010, 12, 910-918.	1.9	59
201	Enhancing Sensitivity of Detection of Immune Responses toMycobacterium lepraePeptides in Whole-Blood Assays. Vaccine Journal, 2010, 17, 993-1004.	3.1	25
202	Induction of regulatory T cells by macrophages is dependent on production of reactive oxygen species. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 17686-17691.	7.1	234
203	Mycobacterium tuberculosis Peptides Presented by HLA-E Molecules Are Targets for Human CD8+ T-Cells with Cytotoxic as well as Regulatory Activity. PLoS Pathogens, 2010, 6, e1000782.	4.7	141
204	First in humans: A new molecularly defined vaccine shows excellent safety and strong induction of long-livedMycobacterium tuberculosis-specific Th1-cell like responses. Hum Vaccin, 2010, 6, 1007-1015.	2.4	55
205	Ag85Bâ€“ESAT-6 adjuvanted with IC31Â® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naÃ¯ve human volunteers. Vaccine, 2010, 28, 3571-3581.	3.8	188
206	MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques. PLoS ONE, 2009, 4, e5264.	2.5	186
207	Identification of Major Factors Influencing ELISpot-Based Monitoring of Cellular Responses to Antigens from Mycobacterium tuberculosis. PLoS ONE, 2009, 4, e7972.	2.5	46
208	Cross-Reactive Immunity to Mycobacterium tuberculosis DosR Regulon-Encoded Antigens in Individuals Infected with Environmental, Nontuberculous Mycobacteria. Infection and Immunity, 2009, 77, 5071-5079.	2.2	54
209	Infection withMycobacterium tuberculosisBeijing Genotype Strains Is Associated with Polymorphisms inSLC11A1/NRAMP1in Indonesian Patients with Tuberculosis. Journal of Infectious Diseases, 2009, 200, 1671-1674.	4.0	72
210	Immunogenicity of Novel DosR Regulon-Encoded Candidate Antigens of Mycobacterium tuberculosis in Three High-Burden Populations in Africa. Vaccine Journal, 2009, 16, 1203-1212.	3.1	148
211	Transcriptional and inflammasomeâ€mediated pathways for the induction of ILâ€1Î² production by Mycobacterium tuberculosis. European Journal of Immunology, 2009, 39, 1914-1922.	2.9	75
212	Overcoming the global crisis: â€œYes, we canâ€, but also for TB â€¦ ?. European Journal of Immunology, 2009, 39, 2014-2020.	2.9	41
213	Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGAâ€“PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice. Vaccine, 2009, 27, 4010-4017.	3.8	103
214	Analysis of Mycobacterium tuberculosis-Specific CD8 T-Cells in Patients with Active Tuberculosis and in Individuals with Latent Infection. PLoS ONE, 2009, 4, e5528.	2.5	88
215	Genetic deficiencies of innate immune signalling in human infectious disease. Lancet Infectious Diseases, The, 2009, 9, 688-698.	9.1	102
216	Identification of T-Cell Antigens Specific for Latent Mycobacterium Tuberculosis Infection. PLoS ONE, 2009, 4, e5590.	2.5	126

#	Article	IF	Citations
217	Not to wake a sleeping giant: new insights into host-pathogen interactions identify new targets for vaccination against latentMycobacterium tuberculosisinfection. Biological Chemistry, 2008, 389, 497-511.	2.5	44
218	Human CD4 and CD8 regulatory T cells in infectious diseases and vaccination. Human Immunology, 2008, 69, 760-770.	2.4	120
219	Human Anti-Inflammatory Macrophages Induce Foxp3+GITR+CD25+ Regulatory T Cells, Which Suppress via Membrane-Bound TGFÎ²-1. Journal of Immunology, 2008, 181, 2220-2226.	0.8	215
220	The ESX-5 Secretion System of Mycobacterium marinum Modulates the Macrophage Response. Journal of Immunology, 2008, 181, 7166-7175.	0.8	131
221	Genetic Association and Expression Studies Indicate a Role of Toll-Like Receptor 8 in Pulmonary Tuberculosis. PLoS Genetics, 2008, 4, e1000218.	3.5	228
222	Influenza Virus Vaccination Induces Interleukin-12/23 Receptor Î²1 (IL-12/23RÎ²1)-Independent Production of Gamma Interferon (IFN-Î³) and Humoral Immunity in Patients with Genetic Deficiencies in IL-12/23RÎ²1 or IFN-Î³ Receptor I. Vaccine Journal, 2008, 15, 1171-1175.	3.1	11
223	Host-Pathogen Interactions in Latent Mycobacterium tuberculosis Infection: Identification of New Targets for Tuberculosis Intervention. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2008, 8, 15-29.	1.2	26
224	T-Cell Recognition of the HspX Protein of Mycobacterium tuberculosis Correlates with Latent M. tuberculosis Infection but Not with M. bovis BCG Vaccination. Infection and Immunity, 2007, 75, 2914-2921.	2.2	107
225	Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8029-8034.	7.1	178
226	Dynamic Changes in Pro- and Anti-Inflammatory Cytokine Profiles and Gamma Interferon Receptor Signaling Integrity Correlate with Tuberculosis Disease Activity and Response to Curative Treatment. Infection and Immunity, 2007, 75, 820-829.	2.2	147
227	Immunogenicity of Eight Dormancy Regulon-Encoded Proteins of Mycobacterium tuberculosis in DNA-Vaccinated and Tuberculosis-Infected Mice. Infection and Immunity, 2007, 75, 941-949.	2.2	138
228	Discrepancy between Mycobacterium tuberculosis -Specific Gamma Interferon Release Assays Using Short and Prolonged In Vitro Incubation. Vaccine Journal, 2007, 14, 880-885.	3.1	107
229	Lack of Immune Responses to Mycobacterium tuberculosis DosR Regulon Proteins following Mycobacterium bovis BCG Vaccination. Infection and Immunity, 2007, 75, 3523-3530.	2.2	96
230	Detection of Mycobacterium leprae infection employing a combinatorial approach of anti-45 kDa and modified anti-PGL-I antibody detection assays. Journal of Medical Microbiology, 2007, 56, 1129-1130.	1.8	2
231	Assessment of Cross-Reactivity between Mycobacterium bovis and M. kansasii ESAT-6 and CFP-10 at the T-Cell Epitope Level. Vaccine Journal, 2007, 14, 1536-1536.	3.1	1
232	Serological heterogeneity against various Mycobacterium leprae antigens and its use in serodiagnosis of leprosy patients. Journal of Medical Microbiology, 2007, 56, 1259-1261.	1.8	2
233	The Effect of Type 2 Diabetes Mellitus on the Presentation and Treatment Response of Pulmonary Tuberculosis. Clinical Infectious Diseases, 2007, 45, 428-435.	5.8	270
234	Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. Nature, 2007, 450, 725-730.	27.8	310

#	Article	IF	Citations
235	Plasma granulysin levels and cellular interferon-Î³ production correlate with curative host responses in tuberculosis, while plasma interferon-Î³ levels correlate with tuberculosis disease activity in adults. Tuberculosis, 2007, 87, 312-321.	1.9	47
236	Association of polymorphisms in IL-12/IFN-Î³ pathway genes with susceptibility to pulmonary tuberculosis in Indonesia. Tuberculosis, 2007, 87, 303-311.	1.9	48
237	Two Patients with Complete Defects in Interferon Gamma Receptor-Dependent Signaling. Journal of Clinical Immunology, 2007, 27, 490-496.	3.8	25
238	HLA and Leprosy in the Pre and Postgenomic Eras. Human Immunology, 2006, 67, 439-445.	2.4	38
239	Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes and Infection, 2006, 8, 2052-2060.	1.9	262
240	Human host genetic factors in mycobacterial and Salmonella infection: lessons from single gene disorders in IL-12/IL-23-dependent signaling that affect innate and adaptive immunity. Microbes and Infection, 2006, 8, 1167-1173.	1.9	47
241	Presentation of Interleukin-12/-23 Receptor Î²1 Deficiency with Various Clinical Symptoms of Salmonella Infections. Journal of Clinical Immunology, 2006, 26, 1-6.	3.8	56
242	Monokine induced by interferon gamma and IFN-Î³ response to a fusion protein of Mycobacterium tuberculosis ESAT-6 and CFP-10 in Brazilian tuberculosis patients. Microbes and Infection, 2006, 8, 45-51.	1.9	46
243	The search for a tuberculosis vaccine: An elusive quest?. Tuberculosis, 2006, 86, 41-46.	1.9	11
244	Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. European Journal of Immunology, 2006, 36, 661-670.	2.9	222
245	Recognition of Stage-Specific Mycobacterial Antigens Differentiates between Acute and Latent Infections with Mycobacterium tuberculosis. Vaccine Journal, 2006, 13, 179-186.	3.1	174
246	Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-Î³- and CD40L-mediated costimulation. Journal of Leukocyte Biology, 2006, 79, 285-293.	3.3	340
247	T cell immune responses to mycobacterial antigens in Brazilian tuberculosis patients and controls. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2005, 99, 699-707.	1.8	22
248	Control of human host immunity to mycobacteria. Tuberculosis, 2005, 85, 53-64.	1.9	158
249	NOD2 and Toll-Like Receptors Are Nonredundant Recognition Systems of Mycobacterium tuberculosis. PLoS Pathogens, 2005, 1, e34.	4.7	304
250	Postgenomic Approach To Identify Novel Mycobacterium leprae Antigens with Potential To Improve Immunodiagnosis of Infection. Infection and Immunity, 2005, 73, 5636-5644.	2.2	59
251	Molecular complementation of IL-12RÎ²1 deficiency reveals functional differences between IL-12RÎ²1 alleles including partial IL-12RÎ²1 deficiency. Human Molecular Genetics, 2005, 14, 3847-3855.	2.9	33
252	Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans. Human Immunology, 2005, 66, 13-20.	2.4	354

#	Article	IF	Citations
253	Leprosy bacillus triggers the wrong cells. International Journal of Leprosy and Other Mycobacterial Diseases, 2005, 73, 208-10.	0.3	1
254	Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 4560-4565.	7.1	834
255	Pneumonia caused by Mycobacterium kansasii in a series of patients without recognised immune defect. Clinical Microbiology and Infection, 2004, 10, 738-748.	6.0	34
256	Interleukin-10 promoter single-nucleotide polymorphisms as markers for disease susceptibility and disease severity in leprosy. Genes and Immunity, 2004, 5, 592-595.	4.1	69
257	Human genetics of intracellular infectious diseases: molecular and cellular immunity against mycobacteria and salmonellae. Lancet Infectious Diseases, The, 2004, 4, 739-749.	9.1	182
258	Study of the antibody response against Mycobacterium tuberculosis antigens in Warao Amerindian children in Venezuela. Memorias Do Instituto Oswaldo Cruz, 2004, 99, 517-524.	1.6	29
259	Genetic variations in the interleukin-12/interleukin-23 receptor (Î²1) chain, and implications for IL-12 and IL-23 receptor structure and function. Immunogenetics, 2003, 54, 817-829.	2.4	48
260	Severe Mycobacterium bovis BCG infections in a large series of novel ILâ€“12 receptor Î²1 deficient patients and evidence for the existence of partial ILâ€“12 receptor Î²1 deficiency. European Journal of Immunology, 2003, 33, 59-69.	2.9	76
261	IL-12 receptor deficiency revisited: IL-23-mediated signaling is also impaired in human genetic IL-12 receptorÎ²1 deficiency. European Journal of Immunology, 2003, 33, 3393-3397.	2.9	29
262	DISSEMINATED MYCOBACTERIUM PEREGRINUM INFECTION IN A CHILD WITH COMPLETE INTERFERON-GAMMA RECEPTOR-1 DEFICIENCY. Pediatric Infectious Disease Journal, 2003, 22, 378-380.	2.0	40
263	Human Deficiencies in Type-1 Cytokine Receptors Reveal the Essential Role of Type-1 Cytokines in Immunity to Intracellular Bacteria. Advances in Experimental Medicine and Biology, 2003, 531, 279-294.	1.6	28
264	Role of Tumor Necrosis Factorâ€“Î± and Interleukinâ€10 Promoter Gene Polymorphisms in Leprosy. Journal of Infectious Diseases, 2002, 186, 1687-1691.	4.0	122
265	Epitope Mapping of the Immunodominant Antigen TB10.4 and the Two Homologous Proteins TB10.3 and TB12.9, Which Constitute a Subfamily of the esat-6 Gene Family. Infection and Immunity, 2002, 70, 5446-5453.	2.2	153
266	Identification and Characterization of the ESAT-6 Homologue of Mycobacterium leprae and T-Cell Cross-Reactivity with Mycobacterium tuberculosis. Infection and Immunity, 2002, 70, 2544-2548.	2.2	126
267	Tuberculin Skin Testing and In Vitro T Cell Responses to ESATâ€6 and Culture Filtrate Protein 10 after Infection withMycobacterium marinumorM. kansasii. Journal of Infectious Diseases, 2002, 186, 1797-1807.	4.0	155
268	Human Host Defense and Cytokines in Mycobacterial Infectious Diseases: Interleukinâ€18 Cannot Compensate for Genetic Defects in the Interleukinâ€12 System. Clinical Infectious Diseases, 2002, 35, 210-212.	5.8	122
269	Innate Immunity toMycobacterium tuberculosis. Clinical Microbiology Reviews, 2002, 15, 294-309.	13.6	511
270	Kinetics of T cell-activation molecules in response to Mycobacterium tuberculosis antigens. Memorias Do Instituto Oswaldo Cruz, 2002, 97, 1097-1099.	1.6	16

#	Article	IF	Citations
271	Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae. Nature Genetics, 2002, 32, 97-105.	21.4	241
272	Mycobacterium leprae-Specific, HLA Class II-Restricted Killing of Human Schwann Cells by CD4+ Th1 Cells: A Novel Immunopathogenic Mechanism of Nerve Damage in Leprosy. Journal of Immunology, 2001, 166, 5883-5888.	0.8	73
273	Repeatedly negative tuberculin skin tests followed by active tuberculosis in an immunocompetent individual. Netherlands Journal of Medicine, 2001, 58, 76-81.	0.5	6
274	Multifocal osteomyelitis caused by nontuberculous mycobacteria in patients with a genetic defect of the interferon-ÃŽÂ³ receptor. Netherlands Journal of Medicine, 2001, 59, 140-151.	0.5	52
275	Natural T-helper immunity against human papillomavirus type 16 (hpv16) e7-derived peptide epitopes in patients with hpv16-positive cervical lesions: Identification of 3 human leukocyte antigen class ii-restricted epitopes. International Journal of Cancer, 2001, 91, 612-618.	5.1	129
276	Tuberculin Skin Testing Compared with T-Cell Responses to Mycobacterium tuberculosis -Specific and Nonspecific Antigens for Detection of Latent Infection in Persons with Recent Tuberculosis Contact. Vaccine Journal, 2001, 8, 1089-1096.	2.6	71
277	Presence of Human T-Cell Responses to the Mycobacterium leprae 45-Kilodalton Antigen Reflects Infection with or Exposure to M. leprae. Vaccine Journal, 2001, 8, 604-611.	2.6	6
278	Use of ESATâ€6 and CFPâ€10 Antigens for Diagnosis of Extrapulmonary Tuberculosis. Journal of Infectious Diseases, 2001, 183, 175-176.	4.0	74
279	Novel mechanisms in the immunopathogenesis of leprosy nerve damage: The role of Schwann cells, T cells and Mycobacterium leprae. Immunology and Cell Biology, 2000, 78, 349-355.	2.3	53
280	Human deficiencies in type 1 cytokine receptors reveal the essential role of type 1 cytokines in immunity to intracellular bacteria. Microbes and Infection, 2000, 2, 1559-1566.	1.9	37
281	Identification of Major Epitopes ofMycobacterium tuberculosisAG85B That Are Recognized by HLA-A*0201-Restricted CD8+ T Cells in HLA-Transgenic Mice and Humans. Journal of Immunology, 2000, 165, 6463-6471.	0.8	152
282	Antigenic Equivalence of Human T-Cell Responses to Mycobacterium tuberculosis -Specific RD1-Encoded Protein Antigens ESAT-6 and Culture Filtrate Protein 10 and to Mixtures of Synthetic Peptides. Infection and Immunity, 2000, 68, 3314-3321.	2.2	171
283	Residual Type 1 Immunity in Patients Genetically Deficient for Interleukin 12 Receptor Î²1 (IL-12RÎ²1). Journal of Experimental Medicine, 2000, 192, 517-528.	8.5	73
284	Purification of His-Tagged Proteins by Immobilized Chelate Affinity Chromatography: The Benefits from the Use of Organic Solvent. Protein Expression and Purification, 2000, 18, 95-99.	1.3	217
285	Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10. Blood, 2000, 95, 3162-3167.	1.4	154
286	ALLORECOGNITION OF ARTIFICIAL NERVE GUIDES FILLED WITH HUMAN SCHWANN CELLS : An In Vitro Pilot Study. Transplantation, 2000, 69, 455.	1.0	1
287	Limitations of homology searching for identification of T-cell antigens with library derived mimicry epitopes. Vaccine, 1999, 18, 204-208.	3.8	6
288	The mammalian cell entry operon 1 (mce1) of Mycobacterium leprae and Mycobacterium tuberculosis. Microbial Pathogenesis, 1999, 27, 173-177.	2.9	23

#	Article	IF	Citations
289	HLA-DR/DQ Transgenic, class II deficient mice as a novel model to select for HSP T cell epitopes with immunotherapeutic or preventative vaccine potential. Biotherapy (Dordrecht, Netherlands), 1998, 10, 191-196.	0.7	12
290	Novel human immunodeficiencies reveal the essential role of type-1 cytokines in immunity to intracellular bacteria. Trends in Immunology, 1998, 19, 491-494.	7.5	283
291	Altered Peptide Ligands of Islet Autoantigen Imogen 38 Inhibit Antigen Specific T Cell Reactivity in Human Type-1 Diabetes. Journal of Autoimmunity, 1998, 11, 353-361.	6.5	26
292	Severe Mycobacterial and Salmonella Infections in Interleukin-12 Receptor-Deficient Patients. Science, 1998, 280, 1435-1438.	12.6	782
293	Modulation of Protective and Pathological Immunity in Mycobacterial Infections. International Archives of Allergy and Immunology, 1997, 113, 400-408.	2.1	10
294	HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading. Current Biology, 1997, 7, 950-957.	3.9	154
295	A sensitive fluorometric assay for quantitatively measuring specific peptide binding to HLA class I and class II molecules. Journal of Immunological Methods, 1997, 200, 89-97.	1.4	30
296	A novel, highly efficient peptide-HLA class I binding assay using unfolded heavy chain molecules: identification of HIV-1 derived peptides that bind to HLA-A*0201 and HLA-A*0301. Journal of Immunological Methods, 1997, 205, 201-209.	1.4	20
297	A DR17-restricted T cell epitope from a secretedMycobacterium tuberculosis antigen only binds to DR17 molecules at neutral pH. European Journal of Immunology, 1997, 27, 842-847.	2.9	14
298	Mannose receptor-mediated uptake of antigens strongly enhances HLA class II-restricted antigen presentation by cultured dendritic cells. European Journal of Immunology, 1997, 27, 2426-2435.	2.9	298
299	Mannose Receptor Mediated Uptake of Antigens Strongly Enhances HLA-Class II Restricted Antigen Presentation by Cultured Dendritic Cells. Advances in Experimental Medicine and Biology, 1997, 417, 171-174.	1.6	34
300	Selective stimulation of T helper 2 cytokine responses by the antiâ€psoriasis agent monomethylfumarate. European Journal of Immunology, 1996, 26, 2067-2074.	2.9	207
301	Immunological and functional characterization of Mycobacterium leprae protein antigens: an overview. Molecular Microbiology, 1995, 18, 791-800.	2.5	35
302	T cell receptor and peptide-contacting residues in the HLA-DR17(3) Î²1 chain. European Journal of Immunology, 1994, 24, 3241-3244.	2.9	21
303	The biologic importance of conserved major histocompatibility complex class II motifs in primates. Human Immunology, 1993, 38, 201-205.	2.4	14
304	Binding of a major T cell epitope of mycobacteria to a specific pocket within HLA-DRw17(DR3) molecules. European Journal of Immunology, 1992, 22, 107-113.	2.9	57
305	Regulation of Mycobacterial Heat-Shock Protein-Reactive T Cells by HLA Class II Molecules: Lessons from Leprosy. Immunological Reviews, 1991, 121, 171-191.	6.0	61
306	Induction of antigen-specific CD4+ HLA-DR-restricted cytotoxic T lymphocytes as well as nonspecific nonrestricted killer cells by the recombinant mycobacterial 65-kDa heat-shock protein. European Journal of Immunology, 1990, 20, 369-377.	2.9	77

#	Article	IF	Citations
307	Human suppressor T cell clones lack CD28. European Journal of Immunology, 1990, 20, 1281-1288.	2.9	30
308	Mycobacterium leprae-specific protein antigens defined by cloned human helper T cells. Nature, 1986, 319, 66-68.	27.8	129
309	Cloned suppressor T cells from a lepromatous leprosy patient suppress Mycobacterium leprae reactive helper T cells. Nature, 1986, 322, 462-464.	27.8	140
310	Development of Human Cell-Based In Vitro Infection Models to Determine the Intracellular Survival of Mycobacterium avium. Frontiers in Cellular and Infection Microbiology, 0, 12, .	3.9	3